Neurology Trials

Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ALXN1720 in adults with generalized Myasthenia Gravis.

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy.

A Phase 3, Randomized, Double-Blind, Parallel-Group, Pacebo-controlled study to determine the efficacy and safety of Milvexian, an Oral Factor Xia Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

Phase 3 study to investigate the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) compared with placebo in participants after an acute non-cardioembolic ischemic stroke or high-risk TIA.

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis

If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com